Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
Identifieur interne : 001543 ( Ncbi/Merge ); précédent : 001542; suivant : 001544Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
Auteurs : Gerd R. Burmester [Allemagne] ; William F. Rigby [États-Unis] ; Ronald F. Van Vollenhoven [Suède] ; Jonathan Kay [États-Unis] ; Andrea Rubbert-Roth [Allemagne] ; Ricardo Blanco [Espagne] ; Alysha Kadva [États-Unis] ; Sophie Dimonaco [Royaume-Uni]Source :
- Annals of the rheumatic diseases [ 1468-2060 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Anticorps monoclonaux humanisés (usage thérapeutique), Antirhumatismaux (usage thérapeutique), Articulations (imagerie diagnostique), Femelle, Gestion de la pharmacothérapie, Humains, Induction de rémission, Mâle, Méthode en double aveugle, Méthotrexate (usage thérapeutique), Polyarthrite rhumatoïde (imagerie diagnostique), Polyarthrite rhumatoïde (traitement médicamenteux), Radiographie, Résultat thérapeutique, Évolution de la maladie.
- MESH :
- imagerie diagnostique : Articulations, Polyarthrite rhumatoïde.
- traitement médicamenteux : Polyarthrite rhumatoïde.
- usage thérapeutique : Anticorps monoclonaux humanisés, Antirhumatismaux, Méthotrexate.
- Adulte, Adulte d'âge moyen, Femelle, Gestion de la pharmacothérapie, Humains, Induction de rémission, Mâle, Méthode en double aveugle, Radiographie, Résultat thérapeutique, Évolution de la maladie.
English descriptors
- KwdEn :
- Adult, Antibodies, Monoclonal, Humanized (therapeutic use), Antirheumatic Agents (therapeutic use), Arthritis, Rheumatoid (diagnostic imaging), Arthritis, Rheumatoid (drug therapy), Disease Progression, Double-Blind Method, Female, Humans, Joints (diagnostic imaging), Male, Medication Therapy Management, Methotrexate (therapeutic use), Middle Aged, Radiography, Remission Induction, Treatment Outcome.
- MESH :
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Methotrexate.
- diagnostic imaging : Arthritis, Rheumatoid, Joints.
- drug therapy : Arthritis, Rheumatoid.
- Adult, Disease Progression, Double-Blind Method, Female, Humans, Male, Medication Therapy Management, Middle Aged, Radiography, Remission Induction, Treatment Outcome.
Abstract
Investigate whether the efficacy and safety of intravenous tocilizumab (TCZ) demonstrated at week 52 in patients with early rheumatoid arthritis (RA) are maintained to week 104.
DOI: 10.1136/annrheumdis-2016-210561
PubMed: 28389552
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000B74
- to stream PubMed, to step Curation: 000B74
- to stream PubMed, to step Checkpoint: 000A10
Links to Exploration step
pubmed:28389552Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.</title><author><name sortKey="Burmester, Gerd R" sort="Burmester, Gerd R" uniqKey="Burmester G" first="Gerd R" last="Burmester">Gerd R. Burmester</name><affiliation wicri:level="3"><nlm:affiliation>Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Rigby, William F" sort="Rigby, William F" uniqKey="Rigby W" first="William F" last="Rigby">William F. Rigby</name><affiliation wicri:level="2"><nlm:affiliation>Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire</wicri:regionArea><placeName><region type="state">New Hampshire</region></placeName></affiliation></author><author><name sortKey="Van Vollenhoven, Ronald F" sort="Van Vollenhoven, Ronald F" uniqKey="Van Vollenhoven R" first="Ronald F" last="Van Vollenhoven">Ronald F. Van Vollenhoven</name><affiliation wicri:level="3"><nlm:affiliation>Karolinska Institute, Stockholm, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Karolinska Institute, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Kay, Jonathan" sort="Kay, Jonathan" uniqKey="Kay J" first="Jonathan" last="Kay">Jonathan Kay</name><affiliation wicri:level="2"><nlm:affiliation>UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Rubbert Roth, Andrea" sort="Rubbert Roth, Andrea" uniqKey="Rubbert Roth A" first="Andrea" last="Rubbert-Roth">Andrea Rubbert-Roth</name><affiliation wicri:level="1"><nlm:affiliation>University of Cologne, Cologne, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>University of Cologne, Cologne</wicri:regionArea><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion></affiliation></author><author><name sortKey="Blanco, Ricardo" sort="Blanco, Ricardo" uniqKey="Blanco R" first="Ricardo" last="Blanco">Ricardo Blanco</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario Marqués de Valdecilla, Santander, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario Marqués de Valdecilla, Santander</wicri:regionArea><wicri:noRegion>Santander</wicri:noRegion></affiliation></author><author><name sortKey="Kadva, Alysha" sort="Kadva, Alysha" uniqKey="Kadva A" first="Alysha" last="Kadva">Alysha Kadva</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, South San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech, South San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Dimonaco, Sophie" sort="Dimonaco, Sophie" uniqKey="Dimonaco S" first="Sophie" last="Dimonaco">Sophie Dimonaco</name><affiliation wicri:level="1"><nlm:affiliation>Roche Products Ltd., Welwyn Garden City, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Roche Products Ltd., Welwyn Garden City</wicri:regionArea><wicri:noRegion>Welwyn Garden City</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28389552</idno><idno type="pmid">28389552</idno><idno type="doi">10.1136/annrheumdis-2016-210561</idno><idno type="wicri:Area/PubMed/Corpus">000B74</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B74</idno><idno type="wicri:Area/PubMed/Curation">000B74</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B74</idno><idno type="wicri:Area/PubMed/Checkpoint">000A10</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A10</idno><idno type="wicri:Area/Ncbi/Merge">001543</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.</title><author><name sortKey="Burmester, Gerd R" sort="Burmester, Gerd R" uniqKey="Burmester G" first="Gerd R" last="Burmester">Gerd R. Burmester</name><affiliation wicri:level="3"><nlm:affiliation>Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Rigby, William F" sort="Rigby, William F" uniqKey="Rigby W" first="William F" last="Rigby">William F. Rigby</name><affiliation wicri:level="2"><nlm:affiliation>Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire</wicri:regionArea><placeName><region type="state">New Hampshire</region></placeName></affiliation></author><author><name sortKey="Van Vollenhoven, Ronald F" sort="Van Vollenhoven, Ronald F" uniqKey="Van Vollenhoven R" first="Ronald F" last="Van Vollenhoven">Ronald F. Van Vollenhoven</name><affiliation wicri:level="3"><nlm:affiliation>Karolinska Institute, Stockholm, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Karolinska Institute, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Kay, Jonathan" sort="Kay, Jonathan" uniqKey="Kay J" first="Jonathan" last="Kay">Jonathan Kay</name><affiliation wicri:level="2"><nlm:affiliation>UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Rubbert Roth, Andrea" sort="Rubbert Roth, Andrea" uniqKey="Rubbert Roth A" first="Andrea" last="Rubbert-Roth">Andrea Rubbert-Roth</name><affiliation wicri:level="1"><nlm:affiliation>University of Cologne, Cologne, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>University of Cologne, Cologne</wicri:regionArea><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion></affiliation></author><author><name sortKey="Blanco, Ricardo" sort="Blanco, Ricardo" uniqKey="Blanco R" first="Ricardo" last="Blanco">Ricardo Blanco</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario Marqués de Valdecilla, Santander, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario Marqués de Valdecilla, Santander</wicri:regionArea><wicri:noRegion>Santander</wicri:noRegion></affiliation></author><author><name sortKey="Kadva, Alysha" sort="Kadva, Alysha" uniqKey="Kadva A" first="Alysha" last="Kadva">Alysha Kadva</name><affiliation wicri:level="2"><nlm:affiliation>Genentech, South San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Genentech, South San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Dimonaco, Sophie" sort="Dimonaco, Sophie" uniqKey="Dimonaco S" first="Sophie" last="Dimonaco">Sophie Dimonaco</name><affiliation wicri:level="1"><nlm:affiliation>Roche Products Ltd., Welwyn Garden City, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Roche Products Ltd., Welwyn Garden City</wicri:regionArea><wicri:noRegion>Welwyn Garden City</wicri:noRegion></affiliation></author></analytic><series><title level="j">Annals of the rheumatic diseases</title><idno type="eISSN">1468-2060</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Arthritis, Rheumatoid (diagnostic imaging)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Disease Progression</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Joints (diagnostic imaging)</term><term>Male</term><term>Medication Therapy Management</term><term>Methotrexate (therapeutic use)</term><term>Middle Aged</term><term>Radiography</term><term>Remission Induction</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Articulations (imagerie diagnostique)</term><term>Femelle</term><term>Gestion de la pharmacothérapie</term><term>Humains</term><term>Induction de rémission</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Méthotrexate (usage thérapeutique)</term><term>Polyarthrite rhumatoïde (imagerie diagnostique)</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term><term>Radiographie</term><term>Résultat thérapeutique</term><term>Évolution de la maladie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term><term>Methotrexate</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Arthritis, Rheumatoid</term><term>Joints</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="imagerie diagnostique" xml:lang="fr"><term>Articulations</term><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term><term>Méthotrexate</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Disease Progression</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Medication Therapy Management</term><term>Middle Aged</term><term>Radiography</term><term>Remission Induction</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Gestion de la pharmacothérapie</term><term>Humains</term><term>Induction de rémission</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Radiographie</term><term>Résultat thérapeutique</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Investigate whether the efficacy and safety of intravenous tocilizumab (TCZ) demonstrated at week 52 in patients with early rheumatoid arthritis (RA) are maintained to week 104.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28389552</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-2060</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>7</Issue><PubDate><Year>2017</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Annals of the rheumatic diseases</Title><ISOAbbreviation>Ann. Rheum. Dis.</ISOAbbreviation></Journal><ArticleTitle>Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.</ArticleTitle><Pagination><MedlinePgn>1279-1284</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/annrheumdis-2016-210561</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Investigate whether the efficacy and safety of intravenous tocilizumab (TCZ) demonstrated at week 52 in patients with early rheumatoid arthritis (RA) are maintained to week 104.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Methotrexate (MTX)-naive patients with early progressive RA were randomly assigned to double-blind 4 mg/kg TCZ+MTX, 8 mg/kg TCZ+MTX, 8 mg/kg TCZ+placebo or placebo+MTX for 104 weeks. Patients not receiving 8 mg/kg TCZ and not achieving Disease Activity Score-28 joints (DAS28-erythrocyte sedimentation rate (ESR)) ≤3.2 at week 52 switched to escape therapy (8 mg/kg TCZ+MTX). Analyses were exploratory.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Intent-to-treat and safety populations included 1157 and 1153 patients, respectively. DAS28-ESR remission (<2.6) rates were maintained from weeks 52 to 104 (eg, 8 mg/kg TCZ+MTX, 49.3% to 47.6%). Placebo+MTX and 4 mg/kg TCZ+MTX escape patients' week 104 response rates were 51.4% and 30.5%, respectively. Inhibition of radiographic progression was maintained with 8 mg/kg TCZ (eg, 8 mg/kg TCZ+MTX mean (SD) change from baseline in modified total Sharp score: 0.13 (1.28), week 52; 0.19 (2.08), week 104). The safety profile of TCZ was consistent with that of previous reports.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients with early RA treated with TCZ monotherapy or TCZ+MTX maintained clinical benefits during their second year of treatment with no new safety signals.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">NCT01007435; Results.</AbstractText><CopyrightInformation>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burmester</LastName><ForeName>Gerd R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rigby</LastName><ForeName>William F</ForeName><Initials>WF</Initials><AffiliationInfo><Affiliation>Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Vollenhoven</LastName><ForeName>Ronald F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kay</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-8970-4260</Identifier><AffiliationInfo><Affiliation>UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubbert-Roth</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blanco</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hospital Universitario Marqués de Valdecilla, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kadva</LastName><ForeName>Alysha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Genentech, South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimonaco</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Roche Products Ltd., Welwyn Garden City, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01007435</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Rheum Dis</MedlineTA><NlmUniqueID>0372355</NlmUniqueID><ISSNLinking>0003-4967</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007596" MajorTopicYN="N">Joints</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054539" MajorTopicYN="N">Medication Therapy Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011859" MajorTopicYN="N">Radiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DMARDs (biologic)</Keyword><Keyword MajorTopicYN="N">Early Rheumatoid Arthritis</Keyword><Keyword MajorTopicYN="N">Methotrexate</Keyword></KeywordList><CoiStatement>Competing interests: GRB has received honoraria from Roche for lectures and consulting. WFR reports grants and personal fees from Roche outside the submitted work. RFvV reports grants from Roche during the conduct of the study; grants from AbbVie, Amgen, BMS, GSK, Pfizer, Roche, UCB; and personal fees from AbbVie, Biotest, BMS, Celgene, Crescendo, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, UCB, and Vertex outside the submitted work. JK reports grants and personal fees from AbbVie, Eli Lilly and Company, Genentech, Pfizer, Roche Laboratories and UCB; and personal fees from Amgen, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Crescendo Bioscience, Epirus Biopharmaceuticals, GlaxoSmithKline, Hospira, Janssen Biotech, Merck Sharp & Dohme, Novartis Pharmaceuticals, Regeneron Pharmaceuticals, Samsung Bioepis and Sandoz outside the submitted work. AR-R reports personal fees from Roche and Chugai during the conduct of the study and personal fees from Pfizer, Lilly, BMS, AbbVie, MSD, UCB, Janssen, Sanofi and Boehringer outside the submitted work. RB reports grants from Roche, Merck Sharp & Dohme and AbbVie outside the submitted work. AK is an employee of Genentech. SD is an employee of Roche Products.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>09</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>02</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>03</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28389552</ArticleId><ArticleId IdType="pii">annrheumdis-2016-210561</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2016-210561</ArticleId><ArticleId IdType="pmc">PMC5530348</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ann Rheum Dis. 2016 Jun;75(6):1081-91</Citation><ArticleIdList><ArticleId IdType="pubmed">26511996</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2008 Mar 22;371(9617):987-97</Citation><ArticleIdList><ArticleId IdType="pubmed">18358926</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2015 Jun;74(6):1037-44</Citation><ArticleIdList><ArticleId IdType="pubmed">24550168</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2017 Jun;76(6):1078-1085</Citation><ArticleIdList><ArticleId IdType="pubmed">28007755</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2010 Sep;62(9):2569-81</Citation><ArticleIdList><ArticleId IdType="pubmed">20872595</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2013 May 4;381(9877):1541-50</Citation><ArticleIdList><ArticleId IdType="pubmed">23515142</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2008 Oct;58(10 ):2968-80</Citation><ArticleIdList><ArticleId IdType="pubmed">18821691</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2014 Mar;73(3):492-509</Citation><ArticleIdList><ArticleId IdType="pubmed">24161836</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Care Res (Hoboken). 2016 Jan;68(1):1-25</Citation><ArticleIdList><ArticleId IdType="pubmed">26545825</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2013 Jan;72 (1):43-50</Citation><ArticleIdList><ArticleId IdType="pubmed">22562983</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2008 Nov;67(11):1516-23</Citation><ArticleIdList><ArticleId IdType="pubmed">18625622</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2010 Jan;69(1):88-96</Citation><ArticleIdList><ArticleId IdType="pubmed">19297346</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2011 Mar;63(3):609-21</Citation><ArticleIdList><ArticleId IdType="pubmed">21360490</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Espagne</li><li>Royaume-Uni</li><li>Suède</li><li>États-Unis</li></country><region><li>Berlin</li><li>Californie</li><li>Massachusetts</li><li>New Hampshire</li><li>Svealand</li></region><settlement><li>Berlin</li><li>Stockholm</li></settlement></list><tree><country name="Allemagne"><region name="Berlin"><name sortKey="Burmester, Gerd R" sort="Burmester, Gerd R" uniqKey="Burmester G" first="Gerd R" last="Burmester">Gerd R. Burmester</name></region><name sortKey="Rubbert Roth, Andrea" sort="Rubbert Roth, Andrea" uniqKey="Rubbert Roth A" first="Andrea" last="Rubbert-Roth">Andrea Rubbert-Roth</name></country><country name="États-Unis"><region name="New Hampshire"><name sortKey="Rigby, William F" sort="Rigby, William F" uniqKey="Rigby W" first="William F" last="Rigby">William F. Rigby</name></region><name sortKey="Kadva, Alysha" sort="Kadva, Alysha" uniqKey="Kadva A" first="Alysha" last="Kadva">Alysha Kadva</name><name sortKey="Kay, Jonathan" sort="Kay, Jonathan" uniqKey="Kay J" first="Jonathan" last="Kay">Jonathan Kay</name></country><country name="Suède"><region name="Svealand"><name sortKey="Van Vollenhoven, Ronald F" sort="Van Vollenhoven, Ronald F" uniqKey="Van Vollenhoven R" first="Ronald F" last="Van Vollenhoven">Ronald F. Van Vollenhoven</name></region></country><country name="Espagne"><noRegion><name sortKey="Blanco, Ricardo" sort="Blanco, Ricardo" uniqKey="Blanco R" first="Ricardo" last="Blanco">Ricardo Blanco</name></noRegion></country><country name="Royaume-Uni"><noRegion><name sortKey="Dimonaco, Sophie" sort="Dimonaco, Sophie" uniqKey="Dimonaco S" first="Sophie" last="Dimonaco">Sophie Dimonaco</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001543 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001543 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:28389552
|texte= Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:28389552" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |